Pediatric Type 2
A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age
Seeking pediatric subjects have been diagnosed with Type 2 Diabetes.
Study Length: 26 Weeks
Target Age/Sex: 10-17, Male and Female
Participants will receive at no cost: Study medication, Study related lab work and medical exams. Subject will also receive a stipend for time/travel related to the study.